A study of serum antibodies raised against morphine (57272) in 35 workers occupationally exposed to opiates at a narcotics manufacturing facility was conducted. Blood sera were collected before and 10 months after an improved respiratory protection program was implemented at the facility and assayed for specific immunoglobulin-G (IgG) antibodies raised morphine using a radioimmunoassay. Inhibition studies using morphine and morphine derivatives utilizing an enzyme linked immunosorbent assay were also performed. At the second sampling, serum samples were six persons employed at the facility in clerical or administrative positions, 18 drug abusers being treated for heroin use, seven burn patients who used morphine sporadically for pain, and three persons in a drug treatment program who were drug free were also analyzed. Serum IgG antimorphine antibody concentrations in the exposed workers before and after implementation of the respiratory protection program were 4.48 and 1.19, expressed as absorbance units (Au), respectively. The decrease was statistically significant. Serum IgG antibody concentrations in the unexposed workers averaged 1.61Au. The antibodies were specifically directed against morphine, although some cross reactivity with the other morphine derivatives was observed. Preliminary results from the subjects in the drug abuse treatment program indicated that serum IgG antimorphine antibody concentrations were significantly elevated. The authors conclude that serum antimorphine antibody concentrations are elevated in persons occupationally exposed to opiate dusts. Elevated concentrations of these antibodies are also found in heroin abusers.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.